|
(2008, 1300 words)
The paper examines the factors that affected the share prices of AstraZeneca and GlaxoSmithKline, placing particular focus on the Company announcement published in the London Stock Exchange. A short overview of the company ratios is given suggesting recommendations for investors.
(2008, 10 000 words)
The main aim of this dissertation is to understand the dynamics of major variables that impact on the success of merger and acquisition across industries from a corporate strategic perspective. The aim has further been divided into specific objectives that include: to understand the dynamics of major variables that impact on the success of merger and acquisition across industries from a corporate strategic perspective; to highlight the corporate strategy in achieving desired results from M&A activities; and in the light of the analysis, develop strategic recommendations for companies that are considering M&A strategy to achieve desired effects. The dissertation includes the following chapters: introduction, literature review, methodology, analysis and findings, and conclusions and recommendations. This dissertation analyses the following mergers: Hewlett-Packard and Apollo, British Petroleum and Amoco, NatWest and Royal Bank of Scotland, Glaxo Wellcome and SmithKline Beecham, Halifax and Bank of Scotland, Banco Santander and Abbey and Boots and Alliance Unichem. Proposal matching this dissertation is also available on our website under the name: C/B/854. Proposal: Do Mergers and Acquisition Always Bring the Desired Effects?
(2008, 10 000 + 1500 words)
The main aim of this dissertation is to understand the dynamics of major variables that impact on the success of merger and acquisition across industries from a corporate strategic perspective. The aim has further been divided into specific objectives that include: to understand the dynamics of major variables that impact on the success of merger and acquisition across industries from a corporate strategic perspective; to highlight the corporate strategy in achieving desired results from M&A activities; and in the light of the analysis develop strategic recommendations for companies that are considering M&A strategy to achieve desired effects The dissertation includes the following chapters: introduction, literature review, methodology, analysis and findings, and conclusions and recommendations. This dissertation analyses the following mergers: Hewlett-Packard and Apollo, British Petroleum and Amoco, NatWest and Royal Bank of Scotland, Glaxo Wellcome and SmithKline Beecham, Halifax and Bank of Scotland, Banco Santander and Abbey and Boots and Alliance Unichem. Proposal for this dissertation is provided in the appendix.
(2008, 1500 words)
The main aim of this proposed project is to understand the dynamics of major variables that impact on the success of merger and acquisition across industries from a corporate strategic perspective. The report includes sections such as introduction, aims and objectives, initial literature review, and methodology based on case studies and secondary data collection. Case studies analysed are: Hewlett-Packard and Apollo, British Petroleum and Amoco, NatWest and Royal Bank of Scotland, Glaxo Wellcome and SmithKline Beecham, Halifax and Bank of Scotland, Banco Santander and Abbey and Boots and Alliance Unichem. Dissertation matching this proposal is also available on our website under the name: C/B/852. Dissertation. Do Mergers and Acquisition Always Bring the Desired Effects?
(2007, 3600 words)
The paper examines the merger of Glaxo Wellcome & SmithKline Beecham, one of the most pronounced within the pharmaceutical industry, in the light of change management theories. The research touches on the cultural theory, leadership theory, change facilitation theory and the techniques of communicating during a change situation.
(2007, 3500 words)
The paper examines the merger of Glaxo Wellcome & SmithKline Beecham, one of the most pronounced within the pharmaceutical industry in the light of change management theories. The research focuses on four major characteristics i.e. cultural theory, leadership theory, facilitating change, and communicating strategy during a change situation.
(2007, 3300 words)
This report has been produced to analyse the negotiations regarding the intellectual property rights agreement between GlaxoSmithKline, one of the leading research based pharmaceutical company and Harbin Pharmaceutical Group Holding Co. Ltd., a state holding Sino Foreign Joint Venture for the drug Cervarix TM, which is vaccine against human papillomavirus (HPV) that causes cervical cancer. The negotiations ended with GSK signing a 15 year contract with Harbin and approved for distribution in Australia in May 2007 for women aged 10 to 45
(2007, 5000 words)
This report has been aimed at understanding the operations that are aimed to improve the speed of research and development (R&D) activities that is a source of sustainable competitive advantage for pharmaceutical industry. The report has been divided into three parts i.e. a) Maps the process out, identifying timings for steps using an appropriate scale and identifies the objectives the process owners had for speeding up the process. b) Investigates whether the attempts to speed up the process have worked, and where perhaps it has not. c) Use of reading and experience to help critically review the attempt to speed the process, considering the limitations of the project and suggesting how company would improve it for the future.
(2007, 3000 words)
This report has been aimed at discussing the impact of using effective risk management strategy in an organizational perspective. In order to achieve this aim, researcher has chosen the research and development (R&D) department of one of the top research-based pharmaceutical companies, GlaxoSmithKline (GSK). The analysis has been divided into two distinct parts where the first part identifies the key sources of uncertainty about performance of R&D department; and the management of these uncertainty sources by GSK and their effectiveness.
(2007, 6000 words)
The aim of this essay is to analyze the appropriateness of the use of Soft System Methodology (SSM) for research based pharmaceuticals in the domain of strategic management. GlaxoSmithKline has been chosen as a case study to understand the dynamics of implications of Soft Systems Thinking (SST) within research-based pharmaceuticals. An in-depth analysis of the company based on Soft System Methodology (SSM) has been presented. The essay uses theoretical backing to argue the appropriateness of soft systems thinking for strategic management. On the other hand, it consolidates the analysis using 'rich diagrams', root definition and conceptual diagrams.
(2007, 1300 words)
This report has been aimed at exploring ways to find equilibrium between control and entrepreneurship, two diametrically opposite concepts having their own advantages for organizations. The case of GlaxoSmithKline has been used for the purpose of this discussion. GSK is among the top 20 FT Global 500 companies and among the top 5 pharmaceutical companies in the world. GSK develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related consumer products.
(2006, 10 500 words)
The dissertation investigates the performance of GlaxoSmithKline (GSK) form their pre-merger through to the post merger periods providing a review of literature on the theory of mergers and acquisitions (M&A), an overview of the pharmaceutical industry and GSK background including their financial and operational review, performance analysis, etc. The methods of research are based on primary (interviews) and secondary data sources. Conclusions are made about the pre and post merger financial, operational, and value creation performance of GSK.
(2006, 2500 words)
The paper reports on the GlaxoSmithKline (GSK) merger in the pharmaceutical industry outlining the rationale behind the merger, reviewing academic approaches to mergers and acquisitions (M&A), the key reason for mergers, etc. The results of the GSK merger are analysed highlighting the successes and failures, and discussing GSK new products and new markets.
(2006, 2000 words)
The purpose of this report is to critically analyze the statement "Operations Management lies at the heart of the organizations ability to perform. It is often the process whereby the strategic visions and goals of the organization are realized. Superior operations management practice often translates into corporate success". In order to achieve the objectives of this report GlaxoSmithKline's research and development (R&D) department is used as a case study.
(2006, 630 words)
Business organisations are entities with many interrelated parts, which can be affected by a variety of factors, namely political, economic, social, technological, legal and ethical. The paper conducts a PESTLE analysis on a GSK and pharmaceutical industry and explains how the analysis might be useful for the firm or the industry's future planning.
(2005, 6000 words)
This paper examines the Global Pharmaceutical industry's overview, sales, regional forecasts and size. The macro-environment through PESTEL while the industry structure is analyzed with the help of Porter's Five Forces. The analysis of GSK, the world's biggest pharmaceutical company, will be presented through a SWOT that will help us understand what is at stake. Merger and post merger problems COMPLEXITY: THE NATURE OF REAL WORLD PROBLEMS and the Paradox formations. This paper is based on the case study from the book by Johnson and Scholes "Exploring Corporate Strategy: text and cases".
(2006, 3500 words)
The paper reports on GlaxoSmithKline (GSK) providing an overview of the company’s background and current activities, and analysing GSK approaches to corporate culture, human resource management, business ethics, crisis management, corporate governance, etc. Critical analysis is conducted of GSK financial performance in the years following the company’s merger.
(2006, 4500 words)
The paper reports on the pharmaceutical company GlaxoSmithKline (GSK) presenting an overview of the pharmaceutical industry, discussing the role of research and development (R&D) departments for pharmaceutical companies, etc. The history of GSK mergers is reviewed providing a critical analysis of the merger process and outlining future opportunities and threats.
(2006, 1500 words)
The paper examines theoretical approaches to portfolio construction applying them to the statistical analysis of the prices of British Petroleum (BP) and GlaxoSmithKline’s (GSK) stocks over 2004 – 2005. Conclusions are made about the advantage of investing in the portfolio rather than in the individual stocks.
(2003, 1000 words)
The paper reports on GlaxoSmithKline (GSK) reviewing the company’s history, cultural beliefs, business environment, ethical principles, organisational structure, financial position, etc.
(2006, 3000 words)
The report critically analyzes and synthesizes best practice in relation to various tools used to map and share existing knowledge within an organization. It looks at there case studies of Nokia, GlaxoSmithKline (GSK) and International Business Machine (IBM). The report has been divided into three major parts, first part deals with the business overview of each company, second part looks at the KM strategy and process adopted by each company and lastly with the help of appropriate literature these strategies and process have been evaluated.
(2006, 7500 words)
The paper reports on the merger of GlaxoSmithKline (GSK), a pharmaceutical company, and SmithKline Beecham providing a literature review on the topics of mergers and acquisitions (M&A), offering an overview of the pharmaceutical industry (Porter’s 5 forces analysis) and GSK (SWOT analysis) and comparing the performance of GSK before and after the merger in terms of financial ratios, strategy and synergies achieved. This paper is based on the case study from the book by Johnson and Scholes "Exploring Corporate Strategy: text and cases ".
(2006, 11000 words)
The dissertation investigates the strategic and financial position of GlaxoSmithKline (GSK), a global pharmaceutical company, examining the options for their future development and advising which of the options is best. Literature is reviewed on the subjects of merger and acquisition, profitability studies, divestiture, etc. The global pharmaceutical industry is analysed using Porter’s 5 forces model. Financial reports of GSK are studied; the history of the company’s mergers and acquisitions is reviewed; the key issues currently affecting GSK are analysed using SWOT; strategic options for GSK further development are discussed offering recommendations about the company restructuring.
(2006, 2500 words)
The paper reports on GlaxoSmithKline (GSK), a pharmaceutical company created from the merger between Glaxo- Wellcome and SmithKline Beecham, discussing the reasons behind the merger, the issues of manufacturing innovative biomedical products, the competition in the medical and consumer healthcare goods industry, the implications of a core competency development, etc.
(2006, 5000 words)
The report is based on the management of change at GSK, one of the largest Pharmaceutical companies in the world. The focus has been given to the post merger integration and cultural changes in the R&D departments of the two legacy companies Glaxo Wellcome and SmithKline Beecham. The report uses number of theoretical models to analyze the management of change adopted by the company.
(2005, 2000 words)
The paper examines the internal and external motivations behind the horizontal mergers in the pharmaceutical industry focusing on the GlaxoWellcome and GSK mergers. An overview of the pharmaceutical sector is provided comparing their mergers with those in the automobile industry.
(2005, 1500 words)
The paper examines the backgrounds of three mergers which resulted in GSK, the world’s second largest pharmaceutical company. The needs behind each merger are analysed highlighting the companies’ problems, resolutions, the success factors and benefits of the merger, etc. Potential problems in pharmaceutical industry and in GSK are identified.
(2006, 2500 words)
This report has been aimed to analyze the current operations of the R&D department at GSK. The analysis is focused on the restructuring of the operations during and after the merger of Glaxo Wellcome and SmithKline Beecham. Slacks ‘five performance objective model has been used as a framework for the analysis. The first part of the report shows effectiveness of the restructuring in the department with the help of ‘polar diagrams. The second part of the report recommends how to further improve the operations of the department under the light of ‘perceived user value PUV.
(2004, 4500 words)
The paper reports on the financial performance of GlaxoSmithKline (GSK), the UK company producing health related goods, analyzing their financial summary for 2003 and comparing it with the previous years along the lines of cash flows, assets levels, profitability ratios, sources of finance, risks, etc. Comparisons with a competitive company Astrazeneca (AZN) are made.
(2005, 5000 words)
In todays competitive global business environment, the increasing number of M&A, (Mergers and acquisitions) has presented companies with a new set of opportunities and challenges to consider. This has made the business world become more demanding as organizational leaders attempt to integrate the business strategies, operations, and cultures of the different companies in order to survive and grow. As a result, several companies and in order to survive are coming together to face the challenges. I shall demonstrate why companies adopt growth strategies and analyze the causes of mergers and acquisitions by illustrating an M&A activity. The company of which I have chosen is GlaxoSmithKline, (GSK), a world leading research-based pharmaceutical and healthcare company. I shall explain why it merged in the pharmaceutical industry and assess through the implementation of several strategic applications whether the merger was a success or a not. I will be discussing several key issues including the effects of globalization with regard to several key issues that played a pivotal role in determining the degree of GSKs performance. Moreover I will discuss the factors affecting the pharmaceutical industry which have a direct effect on the decisions that GSK took. The following essay provides an analysis and theoretical understanding of the corporate world. Finally I shall come to a conclusion in which I will asses whether the company that I have chosen has a prospective future and whether it is able to sustain a competitive advantage through the adoption of its strategy.
(2005, 3000 words)
This report analyzes using different tools and models the impact and management of cultural change at GlaxoSmithKline after the merger in 2000. It highlights the cultural changes at research and development department of GSK, outlines the impact it is having on the organization and identifies the issues that this change is creating. The analysis is based upon in-depth discussion of change management process with the help of relevant models and figures. The report concludes with recommendations for the smooth transformation at GSK.
(2003, 8000 words)
This dissertation performs a research of a merger case of GlaxoSmithKline, a pharmaceutical company and examines the impact of the merger on the companys performance in terms of economic benefits and value creation. The research is performed on a base of the companys financial data and publications, literature review in the related area and of the questionnaire survey. First, strategic and economic reasons for mergers in the whole were considered, for this, the empirical evidence of the case companys financial performance was highlighted. Next, benefits of GlaxoSmithKline after the merger have been analysed from the economic, functional, financial and strategic perspectives. Finally, the paper makes a summary and concludes about the benefits the company received after the merge in the long-term range.
(2004, 5000 words)
This report provides a detailed analysis of the GSK (GlaxoSmithKlein) merger in terms of change management. It considers the original status of companies involved before the merger, provides the overview for the company and pharmaceutical market, the transformational process and contemporary status of the company, comprehensively analysing (using Forcefield Analysis analyses as one of the tools as well as other academic models) the particular changes which took place within the company speculating upon the current and future outcomes. The report also includes PEST and SWOT analyses. This paper is based on the case study from the book by Johnson and Scholes "Exploring Corporate Strategy: text and cases ".
(2004, 7500 words)
In January 2000 the merger of SmithKline Beecham PLC and Glaxo Wellcome PLC has been announced. The dissertation aims to analyse the effect of a merger announcement on the stock return of Glaxo Wellcome plc
(2003, 2200 words)
The paper analyses International Finance and Accounting Currency Forecasting and Strategy Project for GlaxoSmithKline Plc (GSK)
(2004, 2000 words)
The aim of the research is to explore the necessary and complementary relationship between total quality and strategic management. Followed by the investigation of the role of quality management (QM) in GSK and how its implementation can be or planned to be improved by the company. The research will also aim to: Outline the links in between quality and strategy in pharmaceutical industry identifying why are they of such a particular concern to the industry and players (including GSK) within it? Follow the historic development of the link in between quality and strategy - what has changed over the decades? What is Quality Management/Total Quality Management in the pharmaceutical sector? What is its significance? Outline the role, procedures and stances of quality management in GSK, tracking the changes within them over the past two decades paying particular interest to the mergers of 1995 and 2000? Learn about and analyse the future trends in the quality management for pharmaceutical sector and GSK in particular from academic and practical sources. Compare and contrast results making conclusions and recommendations for the future. Possibly outline any threats or opportunities for the company, arising from the findings and analysis.
(2003, 7000 words)
This report presents the detailed investigation of the global pharmaceutical industry and analyses the ways in which technological innovation and issues of corporate social responsibility affect the industry. Report consists of the following sections: pharmaceutical industry analysis, pricing strategies, Research and Development in pharmaceutical industry, factors, which affect the companies operating in the industry, types of innovations (internal and external) in the industry future challenges, issues of corporate social responsibility which affect the industry and recommendations onto future development of the industry and companies.
(2004, 4000 words)
This report is analysing the programs implemented by GSK in dealing with change during the course of two mergers and in between and after them. It consists of Pharmaceutical Industry Overview and Trends, overview and analysis of GlaxoSmithKline (GSK), analysis of how company manages changes, introduction of knowledge management at Glaxo, Formation of GlaxoSmithKline, Analysis of Change involved in GSK Merger: Forcefield Analysis, Knowledge Management and Knowledge Capital, Total Quality Management and Cultural Web of GlaxoSmithKline and Styles of Managing Change at GSK. This paper is based on the case study from the book by Johnson and Scholes "Exploring Corporate Strategy: text and cases ".
(2003, 3000 words)
This paper consists of analysis of Pharmaceutical Industry Trends, analysis of Pharmaceutical Markets, investigation of Pharmaceutical Companies performance, Comment on External and Internal Metrics, GlaxoSmithKline today , The Merger and Expected Benefits and Costs, Share Prices Performance , Comparison of Market and Book value of a company and TSR. Conclusion GlaxoSmithKline stock has not performed well since the beginning of the year 2000 and TSR for the corresponding period has been negative. It does not however imply that dismal performance is attributable solely to the merger, as the share price began its descent in the end of 1998, before a merger was announced. It is however apparent that benefits of the merger have failed to become substantial enough to reverse investors expectations about the group and deliver returns above expectations.
|
